相关实验视频

Updated: Jul 27, 2025

Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes

Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes

Published on: June 3, 2018

超增强剂驱动的lncRNA Snhg7通过Tbx5/GLS2/ferroptosis轴加剧心脏缩

Qianhui Zhang¹, Chao Song², Meitian Zhang¹

¹Department of Pharmacology, Harbin Medical University-Daqing, Daqing, 163319, China.

European journal of pharmacology

|June 5, 2023

概括

长非编码RNA Snhg7通过诱导铁亡来驱动心脏缩. 它与Tbx5相互作用以调节GLS2表达,为心脏病提供潜在的治疗点.

科学领域:

心血管生物学心血管生物学
分子生物学分子生物学
表观遗传学在表观遗传学中,表观遗传学是指表观遗传学.

背景情况:

在心脏病中观察到长非编码RNAs (lncRNAs) 的异常表达.
在心脏缩中 lncRNAs 的特定作用仍然在很大程度上未被探索.

研究的目的:

为了识别与心脏缩有关的特定 lncRNA.
阐明 lncRNA 在这种条件下起作用的基础分子机制.

主要方法:

染色体免疫沉测序 (ChIP-seq) 用于识别超强增强剂驱动的基因.
研究 lncRNA-蛋白相互作用和下游转录调节.
评估铁灭症标志物和心肌细胞功能.

主要成果:

lncRNA Snhg7被确定为心脏缩中的超强增强器驱动基因.
lncRNA Snhg7通过与T盒转录因子5 (Tbx5) 相互作用,促进铁亡.
Tbx5调节了谷氨酸酶2 (GLS2) 的表达,影响心肌细胞铁亡.

结论:

lncRNA Snhg7是心脏缩中的新型功能 lncRNA,可能通过铁死来调节这种情况.
确定的机制涉及 lncRNA Snhg7 在心肌细胞中通过转录调节 Tbx5/GLS2/ferroptosis轴.
抑制lncRNA Snhg7为心脏缩提供了一个潜在的治疗策略.

关键词:

心脏过度缩小的情况.铁化是铁化的一种.在 LncRNA Snhg7 Nkx2-5-5 在线观看超级增强剂超级增强剂在Tbx5中使用.

更多相关视频

Viral Transgene Expression in Rodent Hearts and the Assessment of Cardiac Arrhythmia Risk

Viral Transgene Expression in Rodent Hearts and the Assessment of Cardiac Arrhythmia Risk

Published on: July 27, 2022

Transverse Aortic Constriction in Mice

Transverse Aortic Constriction in Mice

Published on: April 21, 2010

相关概念视频

lncRNA - Long Non-coding RNAs

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...

Heart Failure II: Pathophysiology

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...

Pathophysiology of Heart Failure

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...